menu
    • menu
    [{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Mitsubishi Chemical Holdings Corporation

    Menu

    Mitsubishi Chemical Holdings Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mitsubishi Chemical Holdings Corporation

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mitsubishi Chemical Holdings Corporation

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Soleo Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma Post-Hoc Analysis of Phase 3 Study Examines Effect of Early Intervention with Edaravo...

                            Details : This post-hoc analysis assessed the double-blind, placebo-controlled 24-week Phase 3 study of edaravone, including an additional 24-week open-label period with all patients receiving IV edaravone.

                            Product Name : Radicava

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2021

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Soleo Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mitsubishi Chemical Holdings Corporation

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mitsubishi Chemical Holdings Corporation

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Soleo Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma America Presents Real-World Experience Outcomes During IV Edaravone Treatment

                            Details : Soleo Health's ability to collect specific data through its proprietary SoleMetrics patient outcomes program proved valuable in helping to elucidate real-world treatment patterns with IV edaravone in the U.S.

                            Product Name : Radicava

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2020

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Soleo Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth